Post

New research · Ophthalmology
Japanese journal of ophthalmology · 14h
StudyJapanese journal of ophthalmology · 2026

Real-world effectiveness and safety of a fixed-dose combination of 0.4% ripasudil and 0.1% brimonidine in the management of uveitic glaucoma.

Sentaro Kusuhara, Wataru Matsumiya, Sotaro Mori … Makoto Nakamura
Read paper
OphthalmologyStudy

Most eyes with uveitic glaucoma had meaningful pressure reduction on RBFC by 12 months

Real-world effectiveness and safety of a fixed-dose combination of 0.4% ripasudil and 0.1% brimonidine in the management of uveitic glaucoma.

Sentaro Kusuhara … Makoto Nakamura
Japanese journal of ophthalmology · 2026
Purpose

To evaluate the real-world use, treatment outcomes, and tolerability of the fixed-dose combination of ripasudil 0.4% and brimonidine 0.1% (RBFC) eye drops in patients with uveitic glaucoma (uveitic glaucoma).

Methods

Single-center retrospective case series.

n = 39 eyes
64%
Results
64%
in most eyes, eye pressure dropped enough to count as meaningful improvement
n = 39 eyes
More results

The median IOP significantly decreased from 19 mmHg at baseline to 14 mmHg at 12 months (p < 0.001), while the median glaucoma drug score showed no significant change, from 3 at baseline to 4 at 12 months (p = 0.562).

A positive correlation was observed between the duration of uveitic glaucoma and the change in IOP at 12 months (rho = 0.539, p < 0.01).

More results

In the subgroup analysis restricted to eyes switched from ripasudil plus brimonidine eye drops to RBFC, IOP showed a decreasing trend (p = 0.057).

No drug-related adverse events were observed, except for transient conjunctival hyperemia.

“
Conclusion

This real-world study in patients with uveitic glaucoma showed that RBFC achieves effective IOP control while reducing treatment burden, with good tolerability, supporting its continued use in uveitic glaucoma management.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment